Antiplatelet agents for preventing and treating pre-eclampsia
The DOI matches its Crossref record.
Abstract
BACKGROUND: Pre-eclampsia is associated with deficient intravascular production of prostacyclin, a vasodilator, and excessive production of thromboxane, a platelet-derived vasoconstrictor and stimulant of platelet aggregation. These observations led to the hypotheses that antiplatelet agents, and low dose aspirin in particular, might prevent or delay the development of pre-eclampsia. OBJECTIVES: To assess the effectiveness and safety of antiplatelet agents when given to women at risk of developing pre-eclampsia, and to those with established pre-eclampsia. SEARCH STRATEGY: This review drew on the search strategy developed for the Pregnancy and Childbirth Group as a whole. The Cochrane Controlled Trials Register was also searched, The Cochrane Library 1999 Issue 1, Embase was searched from 1994-1999 and hand searches were performed of the congress proceedings of the International and European Societies for the Study of Hypertension in Pregnancy. SELECTION CRITERIA: All randomised trials comparing antiplatelet agents with either placebo or no antiplatelet agent during pregnancy. Quasi random study designs were excluded. Participants were pregnant women considered to be at risk of developing pre-eclampsia, and those with pre-eclampsia before delivery. Women treated postpartum were excluded. Interventions were any comparisons of an antiplatelet agent (such as low dose aspirin or dipyridamole) with either placebo or no antiplatelet agent. DATA COLLECTION AND ANALYSIS: Assessment of trials for inclusion in the review and extraction of data was performed independently and unblinded by two reviewers. Data were entered into the Review Manager software and double checked. MAIN RESULTS: Forty two trials involving over 32,000 women were included in this review, with 30,563 women in the prevention trials. There is a 15% reduction in the risk of pre-eclampsia associated with the use of antiplatelet agents [32 trials with 29,331 women; relative risk (RR) 0.85, 95% confidence interval (0.78, 0.92); Number needed to treat (NNT) 89, (59, 167)]. This reduction is regardless of risk status at trial entry or whether a placebo was used, and irrespective of the dose of asprin or gestation at randomisation. Twenty three trials (28,268 women) reported preterm delivery. There is a small (8%) reduction in the risk of delivery before 37 completed weeks [RR 0.92, (0.88, 0.97); NNT 72 (44, 200)]. Baby deaths were reported in 30 trials (30,093 women). Overall there is a 14% reduction in baby deaths in the antiplatelet group [RR 0.86, (0. 75, 0.98); NNT 250 (125, >10000)]. Small for gestational age babies were reported in 25 trials (20,349 women), with no overall difference between the groups, RR 0.92, (0.84, 1.01). There were no significant differences between treatment and control groups in any other measures of outcome. Five trials compared antiplatelet agents with placebo or no antiplatelet agent for the treatment of pre-eclampsia. There are insufficient data for any firm conclusions about the possible effects of these agents when used for treatment of pre-eclampsia. REVIEWER'S CONCLUSIONS: Antiplatelet agents, in this review largely low dose aspirin, have small-moderate benefits when used for prevention of pre-eclampsia. Further information is required to assess which women are most likely to benefit, when treatment should be started, and at what dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sibai, B., Dekker, G., & Kupferminc, M. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17987-2 · Cited by 1,814
Antiplatelet agents for preventing pre-eclampsia and its complications
Duley, L., Henderson-Smart, D. J., Meher, S., & King, J. F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004659.pub2 · Cited by 1,016
Self-citationCarroli, G., Rooney, C., & Villar, J. (2001) · Paediatric and Perinatal Epidemiology · doi:10.1046/j.1365-3016.2001.0150s1001.x · Cited by 622
Osungbade, K. O., & Ige, O. K. (2011) · Journal of Pregnancy · doi:10.1155/2011/481095 · Cited by 429
Shah, D. A., & Khalil, R. A. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.012 · Cited by 422
Antiplatelet agents for preventing pre-eclampsia and its complications
Duley, L., Meher, S., Hunter, K. E., Seidler, A. L., & Askie, L. M. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004659.pub3 · Cited by 366
Self-citationReliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
Collins, R., & MacMahon, S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03651-5 · Cited by 337
Antioxidants for preventing pre-eclampsia
Rumbold, A., Duley, L., Crowther, C. A., & Haslam, R. R. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004227.pub3 · Cited by 306
Self-citationAntihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., Steyn, D. W., & Henderson-Smart, D. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub2 · Cited by 263
Self-citationAntiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review
Duley, L., Henderson-Smart, D., Knight, M., & King, J. (2001) · BMJ · doi:10.1136/bmj.322.7282.329 · Cited by 241
Self-citationBed rest with or without hospitalisation for hypertension during pregnancy
Meher, S., Abalos, E., & Carroli, G. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003514.pub2 · Cited by 80
Metadata
- Authors
- Knight, M., Duley, L., Henderson-Smart, D., & King, J.
- Venue
- The Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2000-04-24
- Issue
- 2
- Pages
- CD000492-CD000492
- OpenAlex
- W1948043968
- Cited by
- 112
- References
- 0
- Type
- reference entry
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.